Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study

Rhea-AI Summary

Artelo Biosciences (NASDAQ: ARTL) is expanding into glaucoma with a fully funded investigator-sponsored trial evaluating ART27.13, with first patient enrollment expected in Q2 2026. The move diversifies the pipeline without shareholder dilution and leverages a peripherally selective CB2-targeting mechanism. Key milestones include ongoing Phase 2 CAReS data and a European patent extending protection through December 2041. The global glaucoma market is projected to reach USD 16.31 billion by 2033, underscoring the commercial opportunity while noting typical early-stage clinical and regulatory risks.

Positive

• Fully funded IST for ART27.13 avoids near-term shareholder dilution
• First patient enrollment in glaucoma study targeted for Q2 2026
• European patent allowance extends ART27.13 formulation protection through Dec 2041
• Addresses a USD 16.31B projected glaucoma market by 2033

Negative

• ART27.13 remains early-stage; clinical success is not guaranteed
• Regulatory pathways for cannabinoid-based ophthalmics are complex and uncertain
• Eventual commercialization will require significant additional investment beyond the IST

Market Reaction – ARTL

+64.11% $7.98 1016.3x vol

15m delay 23 alerts

+64.11% Since News

$7.98 Last Price

$6.10 $8.34 Day Range

+$2M Valuation Impact

$6M Market Cap

1016.3x Rel. Volume

Following this news, ARTL has gained 64.11%, reflecting a significant positive market reaction. Our momentum scanner has triggered 23 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $7.98. This price movement has added approximately $2M to the company's valuation. Trading volume is exceptionally heavy at 1016.3x the average, suggesting very strong buying interest.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Glaucoma market 2025: $9.46 billion Glaucoma market 2033: $16.31 billion Glaucoma CAGR: 7.05% +5 more

8 metrics

Glaucoma market 2025 $9.46 billion Global glaucoma market value in 2025

Glaucoma market 2033 $16.31 billion Projected global glaucoma market by 2033

Glaucoma CAGR 7.05% Projected 2025–2033 global glaucoma market CAGR

Global patients 2021 145.9 million People affected by glaucoma worldwide in 2021

Global patients 2026 166 million Projected worldwide glaucoma cases by 2026

U.S. glaucoma 2022 4.2 million U.S. adults with glaucoma in 2022

U.S. vision impairment 1.5 million U.S. glaucoma patients with vision impairment in 2022

Patent term ART27.13 Through December 2041 European patent protection on ART27.13 formulation

Market Reality Check

Price: $4.85 Vol: Volume 32,593 is close to...

normal vol

$4.85 Last Close

Volume Volume 32,593 is close to the 34,390 share 20‑day average, indicating typical trading activity into this news. normal

Technical Shares at $4.85 are trading below the $15.52 200‑day MA and remain far under the $85.80 52‑week high.

Peers on Argus

ARTL gained 16.87% while momentum‑flagged peers were mixed: CDIO up 4.44% and EN...

1 Up 1 Down

ARTL gained 16.87% while momentum‑flagged peers were mixed: CDIO up 4.44% and ENSC down 2.48%, pointing to a stock‑specific reaction.

Previous Clinical trial Reports

5 past events · Latest: Oct 15 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Oct 15	Clinical data presentations	Positive	+1.4%	Expanded clinical data on ART26.12 and interim ART27.13 results presented at summit.
Sep 29	Phase 2 data update	Positive	+6.2%	Positive interim Phase 2 CAReS data for ART27.13 in cancer anorexia‑cachexia.
Sep 10	Preclinical data publication	Positive	+3.2%	Preclinical ART12.11 data showed superior efficacy and bioavailability vs CBD alone.
Sep 03	Phase 2 interim results	Positive	-3.2%	Positive Phase 2 CAReS interim results and partnering outlook for ART27.13 in CACS.
Sep 03	Phase 2 interim results	Positive	-3.2%	Interim CAReS data showed weight and lean mass gains for ART27.13 in CACS.

Pattern Detected

Clinical trial updates have more often led to gains, but with several past instances of negative reactions to positive data.

Recent Company History

Over the past months, Artelo released multiple positive clinical data updates across ART26.12, ART27.13, and ART12.11. Events on Sep 3, 2025 and Sep 10, 2025 highlighted strong efficacy and partnering interest, with mixed share‑price follow‑through. Today’s glaucoma IST announcement adds a new ophthalmology indication for ART27.13, extending prior cancer‑related anorexia work into a larger, distinct patient population while continuing the company’s cannabinoid‑focused clinical strategy.

Historical Comparison

+0.9% avg move · Past clinical‑trial headlines moved ARTL about 0.89% on average. Today’s 16.87% gain on the glaucoma...

clinical trial

+0.9%

Average Historical Move clinical trial

Past clinical‑trial headlines moved ARTL about 0.89% on average. Today’s 16.87% gain on the glaucoma IST news is a much stronger reaction than prior similar updates.

Clinical news has tracked a progression from preclinical and early ART26.12/ART12.11 data to multiple interim Phase 2 readouts for ART27.13 in cancer anorexia, with the current update extending ART27.13 into glaucoma via an investigator‑sponsored trial.

Market Pulse Summary

The stock is surging +64.1% following this news. A strong positive reaction aligns with the favorabl...

Analysis

The stock is surging +64.1% following this news. A strong positive reaction aligns with the favorable, non‑dilutive glaucoma IST announcement and Artelo’s prior pattern of gains on some clinical updates. The 16.87% move is far above the historical clinical‑tag average of 0.89%, making it an outlier. Given the company’s small market capitalization and early‑stage pipeline, past volatility patterns suggest that sharp spikes could reverse if future data or funding news disappoint.

Key Terms

investigator-sponsored trial, intraocular pressure, cross-over study, phase 2, +3 more

7 terms

investigator-sponsored trial clinical

"The investigator-sponsored trial (IST) is backed by Glaucoma UK..."

An investigator-sponsored trial is a clinical study that is designed, run and overseen by a doctor or research team at a hospital or university rather than by a drug or device company. For investors it matters because such trials can provide independent tests of a treatment’s benefits or risks, like a third-party review, and can affect a product’s perceived value, regulatory path and future revenue potential without the company bearing full control or cost.

intraocular pressure medical

"Standard-of-care treatments focus primarily on lowering intraocular pressure (IOP)..."

Intraocular pressure is the fluid pressure inside the eye, similar to the air pressure in a tire or the tension in a water balloon that helps the eye keep its shape. It matters to investors because sustained high pressure can lead to glaucoma and vision loss, driving demand for drugs, surgical devices, diagnostics and related regulatory approvals and reimbursements, which directly affect company revenues and risk profiles.

cross-over study clinical

"A Pilot, Randomized, Cross-Over Study to Determine the Effects..."

A cross-over study is a type of clinical trial where each participant receives two or more treatments in sequence, switching from one to another after a set period so each person serves as their own comparison. For investors, this design can sharpen understanding of a drug’s effects with fewer patients and clearer comparisons, which may speed decision-making about a program’s potential and reduce the risk that results are driven by differences between separate patient groups.

phase 2 clinical

"Positive interim Phase 2 data from the CAReS trial demonstrated improvements..."

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

notice of allowance regulatory

"Artelo recently received a Notice of Allowance from the European Patent Office..."

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

patent protection regulatory

"extending patent protection through December 2041."

Patent protection is a government-granted exclusive right that prevents others from making, using, selling or importing a new invention for a limited time, like putting a product in a locked display case that only the inventor can open. For investors, it matters because this exclusivity can secure future sales and profits, justify higher valuation, and reduce competition risk while the patent lasts; loss or challenge of protection can sharply change a company’s potential revenue.

neuroprotective medical

"neuroprotective properties, offering a therapeutic mechanism that goes beyond..."

Neuroprotective describes a drug, treatment, or compound that helps protect nerve cells from injury, degeneration, or death and can slow or prevent loss of brain or nervous-system function. For investors, claims of neuroprotective activity matter because they suggest a therapy could address chronic or progressive conditions (like those that worsen over time), potentially creating long-term demand, higher development hurdles, and regulatory scrutiny; think of it as a shield for neurons that could change a product’s market value.

AI-generated analysis. Not financial advice.

Investigator-sponsored trial backed by Glaucoma UK and HSC R&D Division targets rapidly growing patient population; first enrollment expected Q2 2026

BRISTOL, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences (NASDAQ: ARTL) has announced its entry into the ophthalmology space with a fully funded clinical study evaluating ART27.13 in glaucoma patients. The investigator-sponsored trial (IST) is backed by Glaucoma UK and the HSC R&D Division, with first patient enrollment anticipated in Q2 2026. The announcement represents a significant pipeline diversification for the San Diego-based clinical-stage biopharmaceutical company — and one that does not require dilutive equity financing from shareholders.

A $16.3 Billion Market Growing Faster Than Its Treatment Options

The global glaucoma market was valued at USD 9.46 billion in 2025 and is projected to reach USD 16.31 billion by 2033, growing at a compound annual growth rate of 7.05%. Approximately 145.9 million people were affected by glaucoma in 2021, a figure expected to climb to 166 million by 2026. In the United States alone, 4.2 million adults had glaucoma in 2022, with 1.5 million experiencing vision impairment. U.S. cases are projected to reach 6.3 million by 2050.

The patient population is expanding faster than treatment innovation — a gap that defines the opportunity Artelo is now pursuing.

Why ART27.13 Is Differentiated

Despite a broad pharmacological toolkit available to clinicians, a significant proportion of glaucoma patients continue to experience disease progression. Standard-of-care treatments focus primarily on lowering intraocular pressure (IOP), leaving the underlying neuroprotective needs of patients unaddressed.

ART27.13 is a peripherally selective synthetic cannabinoid receptor agonist. Preclinical data indicates the compound can modulate IOP through aqueous humor dynamics and ocular blood outflow — without the central nervous system side effects that have historically prevented cannabinoid-based therapies from gaining clinical traction in ophthalmology. ART27.13 targets CB2 receptors specifically, which mediate anti-inflammatory, anti-apoptotic, and neuroprotective properties, offering a therapeutic mechanism that goes beyond simple pressure reduction.

The science supporting cannabinoid-based glaucoma treatment has existed since the 1970s. Peripheral selectivity and the CB2-targeting design are what distinguish theoretical benefit from clinical viability.

Capital-Efficient Development: The IST Model

The study will be led by Professor Augusto Azuara-Blanco at Queen's University Belfast and conducted by the Northern Ireland Clinical Trials Unit under the title: "A Pilot, Randomized, Cross-Over Study to Determine the Effects of an Oral, Peripherally Selective, Synthetic Cannabinoid ART27.13 on Intraocular Pressure."

The investigator-sponsored trial structure shifts the financial burden of the study while Artelo maintains strategic control and retains data rights. For capital-constrained biotech companies, ISTs provide an accelerated path to product validation and pipeline de-risking without shareholder dilution. The cross-over study design allows each patient to serve as their own control, increasing statistical power while reducing required enrollment numbers and accelerating timelines.

"This collaboration broadens ART27.13's therapeutic profile beyond cancer-related anorexia while preserving our internal focus on the lead indication."

— Greg D. Gorgas, President and CEO, Artelo Biosciences

Pipeline Momentum Across Multiple Programs

ART27.13 is not a single-indication bet. Positive interim Phase 2 data from the CAReS trial demonstrated improvements in body weight, lean body mass, and physical activity alongside a favorable side-effect profile in cancer-related anorexia patients — particularly at the highest dose tested compared to placebo participants. These results demonstrate proof-of-concept for the compound's mechanism.

In addition, Artelo recently received a Notice of Allowance from the European Patent Office covering the intended commercial formulation of ART27.13, extending patent protection through December 2041. The company's diversified pipeline targets lipid-signaling pathways addressing unmet needs across oncology, pain, dermatology, and neurological conditions.

Key Milestones to Watch

Q2 2026: First patient enrollment in the glaucoma pilot study.

Ongoing: Phase 2 CAReS trial continuation in cancer-related anorexia.

Through 2041: European patent protection on the ART27.13 commercial formulation.

Risk Considerations

As with all early-stage clinical development, this study carries inherent risk. Positive preclinical data does not guarantee clinical success, and regulatory pathways for cannabinoid-based therapies remain complex. Eventual commercialization will require significant additional investment. The IST structure reduces near-term cash burn but does not eliminate long-term capital requirements. Investors are encouraged to review Artelo's full SEC filings and risk disclosures before making investment decisions.

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based clinical-stage biopharmaceutical company focused on developing and commercializing treatments intended to modulate the endocannabinoid system (ECS). The company's pipeline leverages leading scientific methodologies to ECS modulation, balances risk across mechanism of action and stages of development, and is designed to maximize stakeholder value. Artelo's management team has a successful history of pharmaceutical development, regulatory approval, and commercialization.

About The Vanderbilt Report

The Vanderbilt Report delivers institutional-grade research and strategic analysis on micro-cap and small-cap public companies. Our editorial team focuses on market opportunity, capital efficiency, and management execution — the criteria that drive long-term value creation for independent investors.

IMPORTANT DISCLOSURE
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. The Vanderbilt Report may hold positions in securities discussed. All investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. Readers should conduct their own due diligence and consult a licensed financial advisor before making investment decisions.

Media Contact:
The Vanderbilt Report
Jake Rivers
media@vanderbiltreport.com

FAQ

What is Artelo (ARTL) announcing about its glaucoma clinical study and timeline?

Artelo is initiating a fully funded investigator-sponsored glaucoma study, with first patient enrollment expected in Q2 2026. According to the company, the cross-over pilot study will be led by Professor Augusto Azuara-Blanco and run by the Northern Ireland Clinical Trials Unit.

How does the fully funded investigator-sponsored trial affect ARTL shareholders?

The fully funded IST reduces the need for dilutive equity financing in the near term. According to the company, the IST shifts study costs while Artelo retains strategic control and data rights, preserving shareholder equity for now.

What makes ART27.13 differentiated for glaucoma compared to existing treatments?

ART27.13 is a peripherally selective synthetic cannabinoid targeting CB2 receptors with potential neuroprotective effects beyond pressure reduction. According to the company, preclinical data show IOP modulation without central nervous system side effects traditionally limiting cannabinoid ophthalmics.

What commercial protections and pipeline milestones does Artelo (ARTL) cite for ART27.13?

Artelo received a Notice of Allowance from the European Patent Office for the ART27.13 formulation, extending protection through December 2041. According to the company, ongoing Phase 2 CAReS data and the glaucoma IST are primary near-term milestones.

How large is the glaucoma market opportunity cited for ARTL's ART27.13 program?

The release cites a global glaucoma market projected to reach USD 16.31 billion by 2033, up from USD 9.46 billion in 2025. According to the company, expanding patient prevalence and limited treatment innovation define the addressable opportunity.